Continuous Glucose Monitoring (CGM) systems offer either real-time monitoring of blood glucose levels (Dexcom G6®, Freestyle Libre 3®, Guardian Connect®, Eversense E3®) or intermittent scanned monitoring, often referred to as a flash CGM (Freestyle Libre 2® and Libre 14 Day® devices). We are beginning to see coverage of CGM devices migrate toward the pharmacy benefit instead of only the medical benefit. This is an effort to improve patient access and corresponds with the transition of tubeless insulin pump products that integrate with CGM devices to the pharmacy benefit. The Centers for Medicare & Medicaid Services (CMS) continue to cover CGM devices under the medical benefit Part B. There are four major manufacturers of CGM devices: Abbott Laboratories (FreeStyle®), Dexcom (Dexcom G6®), Medtronic (Guardian Connect®), and Ascensia Diabetes Care (Eversense E3®). Depending on the product and type of technology, the wholesale acquisition cost can range from as little as $122 per month up to approximately $700 per month for the device components.